Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis.
暂无分享,去创建一个
Sean Ekins | Barry A. Bunin | Tanya Parish | Barry A Bunin | S. Ekins | T. Parish | D. Roberts | Allen C Casey | David Roberts | A. Casey
[1] Robert Nadon,et al. Statistical practice in high-throughput screening data analysis , 2006, Nature Biotechnology.
[2] Sean Ekins,et al. Combining Cheminformatics Methods and Pathway Analysis to Identify Molecules with Whole-Cell Activity Against Mycobacterium Tuberculosis , 2012, Pharmaceutical Research.
[3] Ann Thayer. TAKING DOWN TB: Even with tools to DIAGNOSE, TREAT, AND PREVENT tuberculosis, the disease remains a significant public health and R&D challenge , 2007 .
[4] David Rogers,et al. Cheminformatics analysis and learning in a data pipelining environment , 2006, Molecular Diversity.
[5] Sean Ekins,et al. Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery , 2013, Pharmaceutical Research.
[6] Hans-Dieter Höltje,et al. Molecular design of two sterol 14α-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole , 2005, J. Comput. Aided Mol. Des..
[7] Julie Clark,et al. Discovery of Novel Antimalarial Compounds Enabled by QSAR-Based Virtual Screening , 2013, J. Chem. Inf. Model..
[8] Andreas Bender,et al. Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. , 2009, Journal of proteome research.
[9] David Beer,et al. A High-Throughput Screen To Identify Inhibitors of ATP Homeostasis in Non-replicating Mycobacterium tuberculosis , 2012, ACS chemical biology.
[10] B Testa,et al. In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.
[11] D. Pompliano,et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.
[12] Noriaki Iwase,et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. , 2012, ACS chemical biology.
[13] G. Schneider,et al. Virtual Screening for Selective Allosteric mGluR1 Antagonists and Structure–Activity Relationship Investigations for Coumarine Derivatives , 2007, ChemMedChem.
[14] Rebecca Voelker,et al. MDR-TB has new drug foe after fast-track approval. , 2013, JAMA.
[15] Gisbert Schneider,et al. Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.
[16] Robert A. Field,et al. New Small-Molecule Synthetic Antimycobacterials , 2005, Antimicrobial Agents and Chemotherapy.
[17] Barry A. Bunin,et al. Chemical Space: Missing Pieces in Cheminformatics , 2010, Pharmaceutical Research.
[18] T. Parish,et al. A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis , 2013, PloS one.
[19] Sean Ekins,et al. Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties , 2010, Drug Metabolism and Disposition.
[20] David John Adams,et al. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans. , 1990, The Biochemical journal.
[21] Sean Ekins,et al. Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5) , 2007, Drug Metabolism and Disposition.
[22] Hélène Decornez,et al. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series. , 2012, Bioorganic & medicinal chemistry.
[23] Sean Ekins,et al. A collaborative database and computational models for tuberculosis drug discovery. , 2010, Molecular bioSystems.
[24] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[25] Alex M. Clark,et al. TB Mobile: a mobile app for anti-tuberculosis molecules with known targets , 2013, Journal of Cheminformatics.
[26] Ying Zhang,et al. The magic bullets and tuberculosis drug targets. , 2005, Annual review of pharmacology and toxicology.
[27] Philip Prathipati,et al. Global Bayesian Models for the Prioritization of Antitubercular Agents , 2008, J. Chem. Inf. Model..
[28] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[29] Lynn Rasmussen,et al. High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv. , 2012, Tuberculosis.
[30] D. Rogers,et al. Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up , 2005, Journal of biomolecular screening.
[31] Andreas Bender,et al. Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..
[32] Barry A. Bunin,et al. Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. , 2013, Chemistry & biology.
[33] Sean Ekins,et al. Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. , 2010, Molecular bioSystems.
[34] Camilla Rodrigues,et al. Totally drug-resistant tuberculosis in India. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] Sean Ekins,et al. Validating New Tuberculosis Computational Models with Public Whole Cell Screening Aerobic Activity Datasets , 2011, Pharmaceutical Research.
[36] Anthony E. Klon,et al. Improved Naïve Bayesian Modeling of Numerical Data for Absorption, Distribution, Metabolism and Excretion (ADME) Property Prediction , 2006, J. Chem. Inf. Model..
[37] Eric Arnoult,et al. The challenge of new drug discovery for tuberculosis , 2011, Nature.
[38] R. Reynolds,et al. High Throughput Screening for Inhibitors of Mycobacterium tuberculosis H 37 Rv , 2012 .
[39] S. Ekins,et al. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.
[40] Vinod Nair,et al. SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.
[41] Hinrich W. H. Göhlmann,et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.
[42] John B. O. Mitchell,et al. Hierarchical virtual screening for the discovery of new molecular scaffolds in antibacterial hit identification , 2012, Journal of The Royal Society Interface.
[43] Lynn Rasmussen,et al. Antituberculosis activity of the molecular libraries screening center network library. , 2009, Tuberculosis.
[44] Sean Ekins,et al. Computational models for tuberculosis drug discovery. , 2013, Methods in molecular biology.
[45] Joel S. Freundlich,et al. Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. , 2011, Trends in Microbiology.
[46] James C. Sacchettini,et al. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis , 2008, Nature Reviews Microbiology.
[47] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[48] Lynn Rasmussen,et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. , 2009, Tuberculosis.
[49] Takushi Kaneko,et al. Challenges and opportunities in developing novel drugs for TB. , 2011, Future medicinal chemistry.
[50] Gisbert Schneider,et al. Comparative virtual screening and novelty detection for NMDA-GlycineB antagonists , 2009, J. Comput. Aided Mol. Des..
[51] Sean Ekins,et al. Enhancing Hit Identification in Mycobacterium tuberculosis Drug Discovery Using Validated Dual-Event Bayesian Models , 2013, PloS one.
[52] S. Ekins,et al. Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.
[53] Giovanni B Migliori,et al. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? , 2012, The Lancet.